Every material Form 8-K ChronoScale Holdings Corp has filed with the SEC since October 02, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
ChronoScale Holdings reported fiscal first quarter 2027 revenue of $41.5 million, up 148% from a year earlier, driven by a new customer's AI infrastructure hardware resale arrangements. Net loss from continuing operations widened to $26.4 million, or $0.18 per share, from $11.2 million, or $0.08 per share, and Adjusted EBITDA fell to $5.9 million from $9.4 million, so shareholders face higher losses even as sales grew.
Revenue was $41.5 million versus $16.7 million in the prior-year quarter, up 148%.
Net loss from continuing operations was $26.4 million, or $0.18 per share, compared with $11.2 million, or $0.08 per share.
Total net loss was $42.5 million, including a $16.1 million loss from discontinued operations tied to the Legacy Ekso Business, which was sold on September 30, 2026.
As of August 31, 2026, cash and cash equivalents were $15.2 million; the company reported $328.2 million in aggregate customer prepayments received after quarter end.
ChronoScale Holdings disclosed that director and Ekso Bionics CEO Scott Davis resigned from the board effective October 3, 2026, following the September 30, 2026 sale of Ekso Bionics. The company granted Davis 51,626 fully vested restricted stock units and agreed to a $709,500 release payment in exchange for a general release of claims, in place of severance he could otherwise have received.
Scott Davis resigned from the board effective October 3, 2026, with no disagreements cited
Davis received 51,626 fully vested RSUs granted October 2, 2026
Release Payment of $709,500, less withholdings, payable within 30 days of signing, subject to compliance with restrictive covenants
Release Agreement replaces payments under a November 5, 2025 Change in Control and Severance Agreement
ChronoScale Holdings completed the sale of its Ekso Bionics subsidiary on September 30, 2026, and said it will focus on its AI infrastructure business. On October 1, 2026, it also announced an expanded agreement with an existing AI infrastructure customer and a new customer agreement, which together with existing contracts provide for $1 billion in annualized revenue run rate by calendar Q3 2027. The filing does not disclose the sale price or the company's profit results, and the revenue run-rate is a non-GAAP measure subject to deployment and financing risks.
Sale of Ekso Bionics, Inc., a wholly owned subsidiary, completed September 30, 2026; the filing does not state the sale price
Expanded AI infrastructure customer agreement and new customer agreement, announced October 1, 2026, with combined contracts targeting $1 billion annualized revenue run rate by calendar Q3 2027
Chief Operating Officer of Ekso, Jason C. Jones, terminated effective September 30, 2026, with severance of $243,750 plus up to nine months of COBRA premiums
Series B Convertible Preferred Stock designation withdrawn September 29, 2026; no preferred shares were outstanding
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every ChronoScale Holdings Corp filing is on SEC EDGAR ↗. 8-K briefs of other companies →